Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

JNJ 125.66 -0.14 (-0.11%)
price chart
Johnson & Johnson Announces Completion of Synthes Acquisition
NEW BRUNSWICK, N.J., June 14, 2012 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Synthes, Inc. for a total purchase price of $19.7 billion in cash and stock.
Johnson & Johnson's Synthes Deal Revives Foreign Tax Debate  Forbes
Johnson & Johnson completes $20B takeover of Synthes
Johnson & Johnson Prostate Cancer Drug Impresses
A new study shows that Johnson & Johnson's prostate cancer pill Zytiga dramatically slows the progression of the disease in men who are not yet sick enough to start chemotherapy.
Johnson & Johnson Latest Company To Break Away From ALEC
Johnson & Johnson is the latest company to break away from the American Legislative Exchange Council (ALEC). On June 12, Johnson & Johnson announced it would stop funding the group that has pushed states to pass voter ID and stand-your-ground ...
Johnson & Johnson Should Split Up Says Goldman
Johnson & Johnson should split into three companies, which could value health-care conglomerate at $76 a share, up more than 20% from current price of $62, Goldman Sachs says.
Johnson & Johnson to stop selling surgical mesh
Johnson & Johnson is stopping sales of surgical mesh products that aimed to relieve the intense pelvic pain of thousands of women but resulted in numerous reports of injury and several deaths.
Johnson & Johnson Unit to Halt Urinary Implants  New York Times
Transvaginal Mesh Lawyer Adam Slater of Mazie Slater Katz & Freeman, LLC ...  PR Web (press release)
Johnson & Johnson: A Lucrative Buy On Synthes Acquisition
Johnson & Johnson (NYSE:JNJ) just announced that it has completed the acquisition of Synthes. The company is the world's largest maker of implants to mend bone fractures and also producer of surgical power tools and advanced biomaterials.
Johnson & Johnson kept selling vaginal mesh implants after warnings
Johnson & Johnson continued to sell a vaginal mesh implant for nine months after U.S. regulators told the company to stop marketing the device, according to court records.
Polaris, J&J Idea to Solve Drug R&D Crisis: Work Together Early
... there are also a lot of experiments going on now to find ways to reform the way drug companies and venture capitalists work together.
J&J, Polaris pact follows series of pharma/VC combos  FierceBiotech
Where's Johnson & Johnson's Growth? Look Internationally
Looking over some of the sales information on Johnson & Johnson (NYSE:JNJ), it's pretty clear that the company is relying more and more on international sales to drive overall revenues.
Baby Soaps and Shampoos Trigger Positive Marijuana Tests
Commonly used baby soaps and shampoos, including products from Johnson & Johnson, Aveeno and CVS, can trigger a positive result on newborns' marijuana screening tests, according to a recent study.
Chemicals in Baby Shampoos Lead to False Marijuana Positives  ABC News
Baby Soap Residue Causing False Positives in Marijuana Tests  Fox News